Related Experiment Video
Updated: Oct 1, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Can extended anticoagulation prophylaxis after discharge prevent thromboembolism?
Muhammad Nadeem Anwar1, Usman Ahmad Khan1, Laura Elizabeth Morris1
1Department of Family and Community Medicine, University of Missouri, Columbia.
Direct oral anticoagulants effectively prevent blood clots in high-risk, nonsurgical patients after hospital discharge. This meta-analysis confirms the benefits of thromboprophylaxis for this patient group.
Area of Science:
- Medical research
- Pharmacology
- Clinical medicine
Background:
- Venous thromboembolism (VTE) is a significant risk for hospitalized patients.
- Nonsurgical patients, particularly those at high risk, face continued VTE risk post-discharge.
- Effective thromboprophylaxis strategies are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of direct oral anticoagulants (DOACs) for thromboprophylaxis.
- To assess the benefit of DOACs in high-risk, nonsurgical patients after hospital discharge.
Main Methods:
- Systematic review and meta-analysis of relevant clinical trials.
- Inclusion of studies focusing on direct oral anticoagulants for VTE prevention.
- Analysis of outcomes in high-risk, nonsurgical patient populations.
Main Results:
- Meta-analysis confirmed a significant benefit of thromboprophylaxis using DOACs.
- DOACs demonstrated effectiveness in reducing VTE events in the studied population.
- The findings support the use of DOACs for extended VTE prophylaxis.
Conclusions:
- Thromboprophylaxis with direct oral anticoagulants is beneficial for high-risk, nonsurgical patients post-discharge.
- DOACs represent an effective option for preventing VTE in this vulnerable group.
- Evidence supports the integration of DOACs into discharge planning for selected patients.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism III: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins

